CRPC-话题@MedSci

#CRPC#

22篇内容 | 1713人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1569864, encodeId=f5ee1569864bc, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, objectType=article, longId=299289, objectId=97bb29928916, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97bb29928916, replyNumber=0, likeNumber=81, createdTime=2022-02-22, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97bb29928916, moduleTitle=Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97bb29928916)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569863, encodeId=13141569863ad, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, objectType=article, longId=221438, objectId=433422143891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=433422143891, replyNumber=0, likeNumber=122, createdTime=2021-12-04, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=433422143891, moduleTitle=Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=433422143891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569862, encodeId=9840156986281, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=Lancet Oncol：阿帕鲁胺联合阿比特龙-泼尼松可明显改善mCRPC患者的生存预后, objectType=article, longId=218148, objectId=fdff218148d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdff218148d4, replyNumber=0, likeNumber=0, createdTime=2021-10-07, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdff218148d4, moduleTitle=Lancet Oncol：阿帕鲁胺联合阿比特龙-泼尼松可明显改善mCRPC患者的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdff218148d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569861, encodeId=6cbe156986110, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=EU：评估哪些mCRPC患者更适合阿比特龙的模型, objectType=article, longId=217639, objectId=674a21e639d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=674a21e639d1, replyNumber=0, likeNumber=88, createdTime=2021-09-26, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=674a21e639d1, moduleTitle=EU：评估哪些mCRPC患者更适合阿比特龙的模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=674a21e639d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569860, encodeId=7698156986019, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=Clin Cancer Res：遗憾！阿特珠单抗+镭-223联合方案未能给mCRPC患者带来额外的临床效益, objectType=article, longId=216703, objectId=fd7e216e0320, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd7e216e0320, replyNumber=0, likeNumber=0, createdTime=2021-09-06, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd7e216e0320, moduleTitle=Clin Cancer Res：遗憾！阿特珠单抗+镭-223联合方案未能给mCRPC患者带来额外的临床效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd7e216e0320)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569859, encodeId=23e11569859fd, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=Eur J Cancer：耄耋之年mCRPC患者采用恩杂鲁胺治疗的效果优于醋酸阿比特龙, objectType=article, longId=212999, objectId=791f2129998e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=791f2129998e, replyNumber=0, likeNumber=84, createdTime=2021-06-22, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=791f2129998e, moduleTitle=Eur J Cancer：耄耋之年mCRPC患者采用恩杂鲁胺治疗的效果优于醋酸阿比特龙, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=791f2129998e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569858, encodeId=35681569858e4, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=ASCO GU 2021：nmCRPC接受恩扎鲁胺治疗患者中PSA下降深度与生存结果密切相关（PROSPER试验）, objectType=article, longId=207162, objectId=89d220e162b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89d220e162b5, replyNumber=0, likeNumber=70, createdTime=2021-02-17, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89d220e162b5, moduleTitle=ASCO GU 2021：nmCRPC接受恩扎鲁胺治疗患者中PSA下降深度与生存结果密切相关（PROSPER试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89d220e162b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569857, encodeId=41c9156985e3b, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处, objectType=article, longId=188104, objectId=396c1881042f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=396c1881042f, replyNumber=0, likeNumber=69, createdTime=2020-02-16, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=396c1881042f, moduleTitle=Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=396c1881042f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569856, encodeId=ece1156985622, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=Prostate Cancer P D：ReACp53靶向突变p53蛋白在CRPC中的治疗潜力, objectType=article, longId=179438, objectId=0b321e943813, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b321e943813, replyNumber=0, likeNumber=85, createdTime=2019-09-16, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b321e943813, moduleTitle=Prostate Cancer P D：ReACp53靶向突变p53蛋白在CRPC中的治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b321e943813)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569855, encodeId=69d615698558e, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=Trovagene在ASCO-GU会议上介绍了Onvansertib与Zytiga联合治疗mCRPC的II期研究, objectType=article, longId=160409, objectId=dada1604094f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dada1604094f, replyNumber=0, likeNumber=62, createdTime=2019-02-20, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dada1604094f, moduleTitle=Trovagene在ASCO-GU会议上介绍了Onvansertib与Zytiga联合治疗mCRPC的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dada1604094f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569854, encodeId=49da1569854f3, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=Oncogene：在CRPC中，KDM8/JMJD5作为AR和PKM2的共激活子参与了AR/EZH2网络和肿瘤代谢, objectType=article, longId=146505, objectId=9bf214650536, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bf214650536, replyNumber=0, likeNumber=63, createdTime=2018-08-14, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bf214650536, moduleTitle=Oncogene：在CRPC中，KDM8/JMJD5作为AR和PKM2的共激活子参与了AR/EZH2网络和肿瘤代谢, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bf214650536)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569853, encodeId=a83b1569853c4, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=HPN424治疗转移性去势抵抗性前列腺癌（mCRPC）的I期临床试验, objectType=article, longId=146129, objectId=b5731461296f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5731461296f, replyNumber=0, likeNumber=52, createdTime=2018-08-09, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5731461296f, moduleTitle=HPN424治疗转移性去势抵抗性前列腺癌（mCRPC）的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5731461296f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569852, encodeId=392f15698524a, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=叶定伟教授：维持去势状态仍然是CRPC患者的基础治疗方法, objectType=article, longId=144127, objectId=d7ad14412e19, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7ad14412e19, replyNumber=0, likeNumber=82, createdTime=2018-07-13, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7ad14412e19, moduleTitle=叶定伟教授：维持去势状态仍然是CRPC患者的基础治疗方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7ad14412e19)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569851, encodeId=5715156985185, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=BJU Int：去势难治性前列腺癌（CRPC）患者中，间断性多烯紫杉醇治疗与持续性多烯紫杉醇治疗比较, objectType=article, longId=136275, objectId=22441362e513, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22441362e513, replyNumber=0, likeNumber=0, createdTime=2018-04-25, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22441362e513, moduleTitle=BJU Int：去势难治性前列腺癌（CRPC）患者中，间断性多烯紫杉醇治疗与持续性多烯紫杉醇治疗比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22441362e513)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569850, encodeId=685a156985088, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=JCO：CRPC患者：低剂量阿比特龙+低脂饮食疗效可与标准方法媲美？, objectType=article, longId=136240, objectId=6c47136240af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c47136240af, replyNumber=0, likeNumber=99, createdTime=2018-04-25, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c47136240af, moduleTitle=JCO：CRPC患者：低剂量阿比特龙+低脂饮食疗效可与标准方法媲美？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c47136240af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569849, encodeId=066715698496f, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=Eur Urol：mCRPC患者外周全血中的AR-V7预测治疗反应。, objectType=article, longId=110753, objectId=4a71110e53ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a71110e53ef, replyNumber=0, likeNumber=79, createdTime=2017-08-26, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a71110e53ef, moduleTitle=Eur Urol：mCRPC患者外周全血中的AR-V7预测治疗反应。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a71110e53ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569848, encodeId=365c1569848db, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=J Clin Oncol：巴他赛 vs 多西他赛一线治疗mCRPC 孰优孰劣？, objectType=article, longId=107937, objectId=e9d610e937e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9d610e937e0, replyNumber=0, likeNumber=65, createdTime=2017-08-08, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9d610e937e0, moduleTitle=J Clin Oncol：巴他赛 vs 多西他赛一线治疗mCRPC 孰优孰劣？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9d610e937e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569847, encodeId=aef2156984e9d, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=J Clin Oncol:卡巴他赛 vs 多西他赛一线治疗mCRPC 孰优孰劣？, objectType=article, longId=107932, objectId=449c10e9323f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=449c10e9323f, replyNumber=0, likeNumber=81, createdTime=2017-08-08, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=449c10e9323f, moduleTitle=J Clin Oncol:卡巴他赛 vs 多西他赛一线治疗mCRPC 孰优孰劣？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=449c10e9323f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569846, encodeId=fc8d156984656, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=Lancet Oncol：mCRPC药物研究：找对评估标准方可获益更多, objectType=article, longId=92071, objectId=a7bc920e145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7bc920e145, replyNumber=0, likeNumber=70, createdTime=2017-03-18, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7bc920e145, moduleTitle=Lancet Oncol：mCRPC药物研究：找对评估标准方可获益更多, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7bc920e145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1569845, encodeId=0c0c1569845cd, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, objectTitle=王杰军：奋进中的中国肿瘤姑息治疗 ——CRPC中国行癌痛专场郑州站, objectType=article, longId=67063, objectId=35586e063d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35586e063d5, replyNumber=0, likeNumber=72, createdTime=2016-04-24, rootId=0, userName=flyingeagle82, userId=5daa15584462, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35586e063d5, moduleTitle=王杰军：奋进中的中国肿瘤姑息治疗 ——CRPC中国行癌痛专场郑州站, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35586e063d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CRPC

2020-05-29

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性

2022-02-22

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性

2021-12-04

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

Lancet Oncol：阿帕鲁胺联合阿比特龙-泼尼松可明显改善mCRPC患者的生存预后

2021-10-07

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

EU：评估哪些mCRPC患者更适合阿比特龙的模型

2021-09-26

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

Clin Cancer Res：遗憾！阿特珠单抗+镭-223联合方案未能给mCRPC患者带来额外的临床效益

2021-09-06

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

Eur J Cancer：耄耋之年mCRPC患者采用恩杂鲁胺治疗的效果优于醋酸阿比特龙

2021-06-22

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

ASCO GU 2021：nmCRPC接受恩扎鲁胺治疗患者中PSA下降深度与生存结果密切相关（PROSPER试验）

2021-02-17

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处

2020-02-16

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

Prostate Cancer P D：ReACp53靶向突变p53蛋白在CRPC中的治疗潜力

2019-09-16

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

Trovagene在ASCO-GU会议上介绍了Onvansertib与Zytiga联合治疗mCRPC的II期研究

2019-02-20

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

Oncogene：在CRPC中，KDM8/JMJD5作为AR和PKM2的共激活子参与了AR/EZH2网络和肿瘤代谢

2018-08-14

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

HPN424治疗转移性去势抵抗性前列腺癌（mCRPC）的I期临床试验

2018-08-09

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

叶定伟教授：维持去势状态仍然是CRPC患者的基础治疗方法

2018-07-13

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

BJU Int：去势难治性前列腺癌（CRPC）患者中，间断性多烯紫杉醇治疗与持续性多烯紫杉醇治疗比较

2018-04-25

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

JCO：CRPC患者：低剂量阿比特龙+低脂饮食疗效可与标准方法媲美？

2018-04-25

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

Eur Urol：mCRPC患者外周全血中的AR-V7预测治疗反应。

2017-08-26

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

J Clin Oncol：巴他赛 vs 多西他赛一线治疗mCRPC 孰优孰劣？

2017-08-08

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

J Clin Oncol:卡巴他赛 vs 多西他赛一线治疗mCRPC 孰优孰劣？

2017-08-08

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

Lancet Oncol：mCRPC药物研究：找对评估标准方可获益更多

2017-03-18

flyingeagle82 (审核中...)

前往app查看评论内容

#CRPC#

王杰军：奋进中的中国肿瘤姑息治疗 ——CRPC中国行癌痛专场郑州站

2016-04-24

科室
- - 订阅+
  - 更多科室
工具
服务